Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAAR: 177Lu-PSMA-617 + Niraparib/Abiraterone in mCRPC
NCT06329830Phase 2Withdrawn
- Sponsor
- Baptist Health South Florida
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib + abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Baptist Health South Florida. Planned start Oct 2024; status: withdrawn.
02
Drugs
niraparib + abiraterone acetate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06329830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329830.